In this webinar, Dr. Sek Kathiresan will share his insights on the practical, real-world translation of genomics for clinical practice and novel therapeutics development.
For common diseases of complex etiology such as myocardial infarction, gene discovery studies have implicated causative genes and validated drug targets. Recently, enthusiasm is growing for front-line applications of common disease genomics for clinical practice and therapeutics development. For instance, polygenic risk scores (PRS) offer the potential to stratify disease susceptibility for broad populations at birth, but strategies for clinical use are under active debate. Furthermore, newer therapeutic modalities such as RNAi or genome editing raise the prospect of more rapid translation of genomic insights into therapies. Dr. Sek Kathiresan, CEO of Verve Therapeutics and Professor of Medicine at Harvard Medical School (on leave), is a world-renowned pioneer in the genomics of cardiovascular disease. In this webinar, he will share his insights on the practical, real-world translation of genomics for clinical practice and novel therapeutics development.
Unless otherwise specifically stated in relation to each and any of the events listed on this page, the MLSC does not host or sponsor these events. The MLSC has no oversight or responsibility for the venue, content or host-organization related to these events. The MLSC has no affiliation with the organizations listing events or with the events, and provides this content and information as a convenience to visitors to the MLSC website.
